Developer docs
API playgroundTry for free, no card

Search company profiles

RAMM Pharma

Full company profile

uuid003un13

Namestring
RAMM Pharma
Legal namestring
Ramm Pharma Corp.
Websiteurl
rammpharma.com
Company typeenum
Public
Founded yearint
1987
Short descriptiontext

RAMM Pharma Corp. is a publicly traded cannabinoid pharmacology company headquartered in Toronto, Canada, that develops and distributes cannabis-based pharmaceutical and hemp products through European subsidiaries Canapar Corp. in Italy and HemPoland in Poland.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cannabinoid pharmaceuticals, hemp oil extraction, CBD product manufacturing, cannabis pharmacology, hemp-derived therapeutics
Industry3 codes
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Cannabinoid Pharmaceuticals
Social media profiles1 record
Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RAMM Pharma is a cannabinoid pharmacology and product formulation company that develops and distributes cannabis-based pharmaceuticals and hemp-derived products. Through its wholly-owned subsidiaries HemPoland (Poland) and Canapar Corp. (Italy), the company manufactures and distributes CBD products and operates hemp oil extraction technologies across European markets.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1CBD products
CategoryCannabinoid products
2European hemp products
CategoryHemp-derived products
3Cannabinoid pharmaceuticals
CategoryCannabinoid pharmaceuticals
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1The Global South S.A.S.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

RAMM Pharma Corp. received minority shareholder approval for a US$5 million investment in The Global South S.A.S. The transaction includes plans to potentially increase ownership to 25% based on future valuation. The deal is pending regulatory approval and is part of RAMM's expansion strategy into cannabinoid pharmaceuticals and hemp products.

globenewswire.com
2Canapar Corp.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RAMM Pharma is acquiring Canapar Corp., a fully integrated European cannabis company based in Italy. The acquisition involves issuing approximately 21.9 million RAMM shares worth about $26.2 million. Canapar is positioned to become one of Europe's largest CBD companies.

poweronecapital.com
Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RAMM Pharma

Cannabinoid Pharmaceuticalsrammpharma.com

RAMM Pharma Corp. is a publicly traded cannabinoid pharmacology company headquartered in Toronto, Canada, that develops and distributes cannabis-based pharmaceutical and hemp products through European subsidiaries Canapar Corp. in Italy and HemPoland in Poland.

RAMM Pharma firmographics

Firmographics
Name
RAMM Pharma
Legal name
Ramm Pharma Corp.
Website
https://rammpharma.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
1–10 employees
Short description
RAMM Pharma Corp. is a publicly traded cannabinoid pharmacology company headquartered in Toronto, Canada, that develops and distributes cannabis-based pharmaceutical and hemp products through European subsidiaries Canapar Corp. in Italy and HemPoland in Poland.
Ownership category
akta.pro rank

RAMM Pharma industry classification

Industry
Product category
Cannabinoid Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Cannabinoid pharmaceuticals
  • Hemp oil extraction
  • CBD product manufacturing
  • Cannabis pharmacology
  • Hemp-derived therapeutics

Where RAMM Pharma is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

RAMM Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

RAMM Pharma product offering

Product offering

Core offering

RAMM Pharma is a cannabinoid pharmacology and product formulation company that develops and distributes cannabis-based pharmaceuticals and hemp-derived products. Through its wholly-owned subsidiaries HemPoland (Poland) and Canapar Corp. (Italy), the company manufactures and distributes CBD products and operates hemp oil extraction technologies across European markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • CBD products
  • European hemp products
  • Cannabinoid pharmaceuticals

Companies that use RAMM Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

RAMM Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

RAMM Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • The Global South S.A.S.coreStrategic or Co-development Partner · 13 November 2025RAMM Pharma Corp. received minority shareholder approval for a US$5 million investment in The Global South S.A.S. The transaction includes plans to potentially increase ownership to 25% based on future valuation. The deal is pending regulatory approval and is part of RAMM's expansion strategy into cannabinoid pharmaceuticals and hemp products.
  • Canapar Corp.coreStrategic or Co-development PartnerRAMM Pharma is acquiring Canapar Corp., a fully integrated European cannabis company based in Italy. The acquisition involves issuing approximately 21.9 million RAMM shares worth about $26.2 million. Canapar is positioned to become one of Europe's largest CBD companies.

Scale indicators4 records

RAMM Pharma competitors and assessment

Company assessment

Market position

Customer concentration

RAMM Pharma social profiles

Digital presence

RAMM Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RAMM Pharma leadership team

Management profile

Number of profiles

RAMM Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

RAMM Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RAMM Pharma M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RAMM Pharma

What does RAMM Pharma do?

RAMM Pharma is a cannabinoid pharmacology and product formulation company that develops and distributes cannabis-based pharmaceuticals and hemp-derived products. Through its wholly-owned subsidiaries HemPoland (Poland) and Canapar Corp. (Italy), the company manufactures and distributes CBD products and operates hemp oil extraction technologies across European markets.

Is RAMM Pharma a public or private company?

RAMM Pharma is a public company. It is classified as public and is currently operating.

When was RAMM Pharma founded?

RAMM Pharma was founded in 1987. It employs 1 to 10 people.

Where is RAMM Pharma based?

RAMM Pharma is headquartered in Toronto, Canada, in the North America region.

Does RAMM Pharma have an API?

No public API is recorded for RAMM Pharma.

What industry is RAMM Pharma in?

RAMM Pharma's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAHAA, CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRAMM Pharma Corp. Receives Minority Shareholder Approval for Proposed Investment Transaction with The Global South S.A.S.RAMM Pharma Corp. announced that its minority shareholders approved a US$5 million investment transaction in The Global South S.A.S. at the company's Special Meeting of Shareholders on November 12, 2025, giving RAMM a 10% equity stake based on a post-investment valuation of US$50 million. The transaction also includes a call option for RAMM to acquire up to an additional 15% equity interest within five years, potentially increasing total ownership to 25% at a future post-money valuation of US$400 million. The company noted it currently lacks the necessary funds to complete the transaction and is considering financing options, with completion subject to definitive documentation and regulatory approvals.GlobeNewswireRAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of ShareholdersRAMM Pharma Corp. disclosed additional details for its proposed $5 million investment in Global South, which would give it a 10% stake with a call option for up to 15% more. The transaction requires minority shareholder approval at a special meeting on November 12, 2025, and the company expects to complete it within nine months.GlobeNewswireRAMM Pharma Corp. Provides Update on Canada post strike and mailing of the Company´s meeting materialsRAMM Pharma Corp. notified shareholders that its meeting materials for the November 12, 2025 special meeting may be delayed due to the Canada Post strike. Materials are available on SEDAR+ and electronically, and shareholders can request control numbers or voting assistance via Odyssey Trust.GlobeNewswireRAMM Pharma Corp. Provides Update on Canada post strike and mailing of the Company´s meeting materialsRAMM Pharma Corp. has notified shareholders that the ongoing Canada Post strike may delay delivery of meeting materials for the Company's Special Meeting scheduled for November 12, 2025. The Company has made materials available electronically and on SEDAR+ as an alternative delivery method, while registered shareholders can contact Odyssey Trust Company directly for voting assistance. This is a procedural shareholder communication addressing logistical disruption rather than a strategic or financial development.GlobeNewswireEarly Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.Jack Burnett filed an early warning report for acquiring 4.667 million common shares of RAMM Pharma for CDN $46.667 million. He now holds 26.72 million shares, representing 22.38% of the company. The acquisition was exempt from take-over bid requirements.GlobeNewswireRAMM Pharma Corp. Provides Update on CanaparRAMM Pharma Corp. is exploring strategic options for the potential sale of its subsidiary Canapar Corp. and/or its industrial facility in Ragusa, Italy. The decision aims to streamline operations and enhance shareholder value, with updates to be provided on an ongoing basis.GlobeNewswireRAMM Pharma Corp. Announces Corporate UpdateRAMM Pharma launched a full line of botanical-derived food supplements through its subsidiary Hempoland under the Marishanti brand. The products, including St. John's Wort and Valerian, are available by April 30, 2024, with EU sales commenced and international expansion planned. Additional mushroom SKUs are under development for 3Q2024 sales.GlobeNewswireRAMM Pharma Corp. Announces Corporate UpdateRAMM Pharma Corp. announced it is cancelling its proposed non-brokered private placement and normal course issuer bid after withdrawing an appeal of a CSE decision. The company had planned to raise up to $1 million and purchase up to 5% of its shares, but the appeal was withdrawn on March 19, 2024.